**** Drug Labelers with Outstanding Balances as reported to CMS ****
**** Tip of the Day ****
Effective January 1, 2015 the Pharmacy Benefit has now been included in
the Managed Care Organization (MCO) package.
UnitedHealthCare Community Plan of Delaware 1-800-842-4195
|Click here for list of State Non-Participating Drug Manufacturers|
|Click here for the DPAP Application form|
*** Drug Rebate Documents *** |
Click here for information on web invoicing: Delaware Web Invoicing Information
*** Please complete both documents for each labeler code when applying for Electronic Invoicing ***
Click here for the application for electronic invoicing
Click here for the current Memorandum of understanding for electronic invoicing
for claim level detail files from 2Q2015 on.
Click here for the previous Memorandum of understanding for electronic invoicing
for claim level detail files between 4Q2011 and 1Q2015.
For questions on web invoicing, email: MoveItDocumentTransfer@hpe.com
*** Current W9 ***
Click here for current W-9 for Drug Rebate
*** Contact Us ***
For any questions related to Drug Rebate, email: DEDrugRebate@hpe.com
Attention Medical and Pharmacy Providers:|
The PDL document has been updated from the November meeting. The updated PDL is under the PDL link on this page, and the dates for each drug class implementation are listed below the category. Please contact Pharmacy Services at 1.800.999.3371 select option 0, select option 1 for further clarification
DMMA with guidance from the Drug Utilization Review Board is addressing overdose deaths that can be directly linked to benzodiazepines. Two policies are going into effect. Therapeutic duplication of benzodiazepines, classified as using two or more of drugs in this class, will now require a prior authorization. Prior authorization for these medications will be needed when there is concomitant use with chronic opioid analgesics. Clinical authorization requests can be submitted in cases that have clear medical necessity and other medical and pharmacological approaches have failed.
Pharmaceutical and Therapeutics (P&T) Committee
The Pharmaceutical and Therapeutics (P&T) Committee has been established by DMMA to provide clinical leadership in the selection of preferred medications. This selection will be based on a review of the relative clinical effectiveness and cost of products within selected therapeutic classes. The program's objective is to achieve quality pharmaceutical care for recipients enrolled in the Department's Medicaid programs while providing significant state savings.
- P & T Committee Meeting -
The Delaware P&T meeting is scheduled for Thursday, September 8th, 2016.
1:30 p.m. - 6:00 p.m.
Delaware Technical Community College
400 Stanton - Christiana Road
Newark, DE 19713
Directions to Stanton Campus
*Times listed are approximations. The public portion of the meeting will start NO EARLIER then the time listed and may be subject to delays.
Please contact Pharmacy Services at 1-800-999-3371 select option 0, select option 1 for further clarification.
Categories for Review